Stock Events

Stock Events

Rhythm Pharmaceuticals 

$88.12
16
+$1.15+1.32% Today

Statistics

Day High
90.8
Day Low
87.18
52W High
122.2
52W Low
45.91
Volume
912,302
Avg. Volume
832,681
Mkt Cap
6.02B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.83
-0.78
-0.72
-0.67
Expected EPS
-0.833405
Actual EPS
N/A

Financials

-106.41%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
379.51MRevenue
-403.83MNet Income

Analyst Ratings

$139.09Average Price Target
The highest estimate is 157.00.
From 11 ratings within the last 6 months. This is not an investment recommendation.
Buy
91%
Hold
9%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RYTM. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap217.54B
Novo Nordisk offers treatments for obesity, a key area Rhythm Pharmaceuticals targets with their weight management drugs.
Lilly(Eli) &
LLY
Mkt Cap772.28B
Eli Lilly has a portfolio of treatments for diabetes and obesity, directly competing with Rhythm's obesity-related therapies.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca develops medications for various metabolic disorders, including obesity, competing in the same therapeutic area as Rhythm.
Merck
MRK
Mkt Cap214.76B
Merck & Co. has a broad portfolio that includes treatments for metabolic disorders and obesity, making them a competitor.
Pfizer
PFE
Mkt Cap140.15B
Pfizer works on metabolic disorders and obesity treatments, areas that overlap with Rhythm Pharmaceuticals' focus.
Sanofi
SNY
Mkt Cap124.45B
Sanofi has a presence in the diabetes and obesity market, competing with Rhythm Pharmaceuticals' products.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline offers products for metabolic disorders, including obesity, competing in the same market as Rhythm.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on innovative treatments, including those for metabolic disorders, positioning them as a competitor.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals works on treatments for obesity and related metabolic disorders, making them a competitor.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals, while primarily known for cystic fibrosis treatments, is expanding into other areas, including metabolic disorders, potentially competing with Rhythm.

About

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. The company was founded in 2008 and is headquartered in Boston, Massachusetts.
Show more...
CEO
Dr. David P. Meeker M.D.
Employees
283
Country
US
ISIN
US76243J1051

Listings

XNAS
US
RYTM
MX
MX
RYTM.MX
F
DE
1RV.F
BOATS
BOATS
RYTM.BOATS

0 Comments

Share your thoughts

FAQ

What is Rhythm Pharmaceuticals stock price today?▼
The current price of RYTM is $88.12 USD — it has increased by +1.32% in the past 24 hours. Watch Rhythm Pharmaceuticals stock price performance more closely on the chart.
What is Rhythm Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Rhythm Pharmaceuticals stocks are traded under the ticker RYTM.
Is Rhythm Pharmaceuticals stock price growing?▼
RYTM stock has risen by +4.14% compared to the previous week, the month change is a -4.97% fall, over the last year Rhythm Pharmaceuticals has showed a +76.24% increase.
What is Rhythm Pharmaceuticals market cap?▼
Today Rhythm Pharmaceuticals has the market capitalization of 6.02B
When is the next Rhythm Pharmaceuticals earnings date?▼
Rhythm Pharmaceuticals is going to release the next earnings report on May 05, 2026.
What were Rhythm Pharmaceuticals earnings last quarter?▼
RYTM earnings for the last quarter are -0.73 USD per share, whereas the estimation was -0.8 USD resulting in a +9.26% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Rhythm Pharmaceuticals revenue for the last year?▼
Rhythm Pharmaceuticals revenue for the last year amounts to 379.51M USD.
What is Rhythm Pharmaceuticals net income for the last year?▼
RYTM net income for the last year is -403.83M USD.
How many employees does Rhythm Pharmaceuticals have?▼
As of April 01, 2026, the company has 283 employees.
In which sector is Rhythm Pharmaceuticals located?▼
Rhythm Pharmaceuticals operates in the Health Care sector.
When did Rhythm Pharmaceuticals complete a stock split?▼
Rhythm Pharmaceuticals has not had any recent stock splits.
Where is Rhythm Pharmaceuticals headquartered?▼
Rhythm Pharmaceuticals is headquartered in Boston, US.